Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial

Authors

Institutions

Publication Details

Journal
Urologic Oncology Seminars and Original Investigations
Published
2025-09-27
DOI
https://doi.org/10.1016/j.urolonc.2025.08.022
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial

Yoshihiko Tomita, Dingwei Ye, Akifumi Fujii, Naohiro Takeuchi
Urologic Oncology Seminars and Original Investigations
Bladder and Urothelial Cancer Treatments
article

Nivolumab plus gemcitabine–cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial

Yoshihiko Tomita, Dingwei Ye, Akifumi Fujii, Naohiro Takeuchi
article en

Abstract

No abstract available for this paper.
Urologic Oncology Seminars and Original InvestigationsVol. 43(12)
Fudan University Shanghai Cancer Center (CN), Ono Pharmaceutical (Japan) (JP), Niigata University (JP)
Openalex Percentile: Top 58%
Bladder and Urothelial Cancer Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.